XML 148 R126.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Contingencies and commitments (Details) $ in Billions |  | 1 Months Ended | 3 Months Ended |  |  |  |  |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Apr. 17, 2023 | Jun. 08, 2021 lawsuit | Apr. 30, 2019 claim lawsuit plaintiff | Dec. 31, 2024 USD ($) installment | Nov. 13, 2024 patent | Oct. 04, 2024 patent | Aug. 12, 2024 patent | May 28, 2024 patent | May 02, 2024 case | Apr. 11, 2024 case | Jan. 10, 2024 patent | Dec. 01, 2023 claim | Mar. 11, 2022 state
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. repatriation tax commitments, number of annual installments | installment |  |  |  | 8 |  |  |  |  |  |  |  |  |
Final U.S. repatriation tax payment | $ |  |  |  | $ 1.8 |  |  |  |  |  |  |  |  |
Amgen Inc. et al. v. Celltrion Inc., et al | Pending Litigation |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Potential number of patents infringed upon |  |  |  |  |  |  |  | 29 |  |  |  |  |
Amgen Inc. et al. v. Samsung Bioepis Co. Ltd., et al | Pending Litigation |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Potential number of patents infringed upon |  |  |  |  |  |  | 34 |  |  |  |  |  |
Amgen Inc. et al. v. Fresenius Kabi USA, LLC et al | Pending Litigation |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Potential number of patents infringed upon |  |  |  |  |  | 33 |  |  |  |  |  |  |
Amgen Inc. et al. v. Accord et al | Pending Litigation |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Potential number of patents infringed upon |  |  |  |  | 34 |  |  |  |  |  |  |  |
Sensipar Antitrust Class Actions | Pending Litigation |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency, number of plaintiffs | plaintiff |  |  | 4 |  |  |  |  |  |  |  |  |  |
Number of lawsuits | claim |  |  | 2 |  |  |  |  |  |  |  |  |  |
Loss contingency, number of lawsuits filed | lawsuit |  |  | 4 |  |  |  |  |  |  |  |  |  |
Number of states in which plaintiffs reside | state |  |  |  |  |  |  |  |  |  |  |  |  | 10
Class action complaint response period | 30 days |  |  |  |  |  |  |  |  |  |  |  |
PAVBLU Patent Litigation | Pending Litigation |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Potential number of patents infringed upon |  |  |  |  |  |  |  |  |  |  | 32 |  |
Number of litigation cases | case |  |  |  |  |  |  |  |  |  | 5 |  |  |
Martin Derivative Action | Pending Litigation |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Loss contingency, number of additional claims | claim |  |  |  |  |  |  |  |  |  |  |  | 2 |
ChemoCentryx, Inc. Securities Matters |  |  |  |  |  |  |  |  |  |  |  |  |
Loss Contingencies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Number of class action law suits | lawsuit |  | 2 |  |  |  |  |  |  |  |  |  |  |
Number of securities cases | case |  |  |  |  |  |  |  |  | 2 |  |  |  |

X
- Definition Loss Contingency, Class Action Complaint Response Period + References No definition available. + Details
Name: | amgn_LossContingencyClassActionComplaintResponsePeriod
Namespace Prefix: | amgn_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Loss Contingency, Number Of Additional Claims + References No definition available. + Details
Name: | amgn_LossContingencyNumberOfAdditionalClaims
Namespace Prefix: | amgn_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Loss Contingency, Number Of Class Action Suits + References No definition available. + Details
Name: | amgn_LossContingencyNumberOfClassActionSuits
Namespace Prefix: | amgn_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Loss Contingency, Number of Lawsuits Filed + References No definition available. + Details
Name: | amgn_LossContingencyNumberOfLawsuitsFiled
Namespace Prefix: | amgn_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Loss Contingency, Number Of Litigation Cases + References No definition available. + Details
Name: | amgn_LossContingencyNumberOfLitigationCases
Namespace Prefix: | amgn_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Loss Contingency, Number Of Securities Cases + References No definition available. + Details
Name: | amgn_LossContingencyNumberOfSecuritiesCases
Namespace Prefix: | amgn_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Loss Contingency, Number Of States In Which Plaintiffs Reside + References No definition available. + Details
Name: | amgn_LossContingencyNumberOfStatesInWhichPlaintiffsReside
Namespace Prefix: | amgn_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Loss Contingency, Potential Patent Infringement, Number + References No definition available. + Details
Name: | amgn_LossContingencyPotentialPatentInfringementNumber
Namespace Prefix: | amgn_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Number Of Annual Installments + References No definition available. + Details
Name: | amgn_TaxCutsAndJobsActOf2017IncompleteAccountingNumberOfAnnualInstallments
Namespace Prefix: | amgn_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Liability, Next Twelve Months + References No definition available. + Details
Name: | amgn_TaxCutsAndJobsActof2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiabilityNextTwelveMonths
Namespace Prefix: | amgn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details
Name: | us-gaap_LossContingenciesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The total number of new claims filed pertaining to a loss contingency during the period. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details
Name: | us-gaap_LossContingencyNewClaimsFiledNumber
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of plaintiffs that have filed claims pertaining to a loss contingency. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details
Name: | us-gaap_LossContingencyNumberOfPlaintiffs
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_LitigationCaseAxis=amgn_AmgenInc.EtAl.V.CelltrionInc.EtAlMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=amgn_AmgenInc.EtAl.V.SamsungBioepisCo.Ltd.EtAlMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=amgn_AmgenInc.EtAl.V.FreseniusKabiUSALLCEtAlMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=amgn_AmgenInc.EtAl.V.AccordEtAlMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=amgn_SensiparAntitrustClassActionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=amgn_PAVBLUPatentLitigationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=amgn_MartinDerivativeActionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_LitigationCaseAxis=amgn_ChemoCentryxIncSecuritiesMattersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |